Earnings and guidance revised upward in tandem, with commercial contracts and capacity expansion strengthening growth visibility

Overview

The report summarizes five key messages from management's conference call and maintains WuXi AppTec Co Ltd as a top pick in China's healthcare industry. The company's revenue from continuing operations grew 48% YoY in the first half of 2026, prompting management to substantially raise full-year growth guidance. Morgan Stanley believes that capacity expansion in small molecules and TIDES, accelerated capital expenditure, AI-driven early-stage drug discovery demand, and continued growth in commercial contracts will support growth in 2026 and beyond.

Core views

The most important growth driver is the expansion of commercial contracts: the company added 12 new commercial contracts in the first half, bringing the total to 95, while small-molecule R&D and manufacturing revenue grew 73% YoY. At the same time, small-molecule and TIDES capacity continues to expand, and the full-year capex budget has been raised, indicating that the company is allocating resources in advance for overseas business, the chemistry business, and subsequent project intake. AI has become an important driver of drug discovery, with customers using the company's experimental services to generate early-stage data, which is expected to drive demand for wet-lab experiments and follow-on R&D services.

Analysis framework

The report assesses growth visibility by combining first-half 2026 financial performance, management's latest full-year guidance, growth and gross margins by business segment, capacity and capex plans, R&D project conversion metrics, and the number of commercial contracts, and uses a discounted cash flow method to estimate base-case value.

Methodology notes

• Valuation methodDiscounted cash flow method

  Estimate enterprise value based on the present value of future free cash flows

  The base case uses a weighted average cost of capital of 10% and a perpetual growth rate of 4%.

• Operating analysisLeading indicator analysis

  Assess future revenue visibility through capacity, contracts, and R&D conversion indicators

  Focuses on small-molecule and TIDES reactor capacity, total commercial contracts, capital expenditure, the number of synthesized compounds, and project conversion from the R stage to the D stage.

• Segment analysisBusiness segment growth and margin analysis

  Compare revenue growth rates and changes in adjusted gross margins across businesses

  The chemistry, testing, and biology businesses all achieved revenue growth in the first half of 2026, with adjusted segment gross margins expanding across the board.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• WuXi AppTec Co Ltd (603259.SS)

  Core covered stock, with Overweight rating and industry top pick view maintained

  Strengths

  High revenue and adjusted profit growth, upgraded full-year guidance, strong chemistry business, continued increase in commercial contracts, small-molecule and TIDES capacity expansion, and incremental demand from AI-driven drug discovery.

  Weaknesses

  Rising capacity expansion and capex scale make future returns more dependent on order growth, project progress, and capacity utilization.

  Comparison

  Morgan Stanley expects the stock's risk-adjusted total return over the next 12 to 18 months to exceed the average of its industry coverage universe.

  Risks

  End-market sales of commercialized projects may fall short of expectations, key products may lose exclusivity, VC/PE financing may fluctuate, and China-US relations may change.

Key data

• Revenue growth in the first half of 202639% YoYRevenue from continuing operations grew 48% YoY.
• Net profit growth in the first half of 202629% YoYAs disclosed in the report.
• Adjusted net profit growth in the first half of 202683% YoYSignificantly faster than revenue growth.
• Full-year revenue growth guidance for continuing operations35% to 39%Previous guidance was 18% to 22%.
• Revenue growth in chemistry, testing, and biology businesses53%, 32%, and 11% YoY, respectivelyAdjusted gross margins expanded across all segments.
• Year-end target capacity for small-molecule reactors5 million litersCurrent capacity exceeds 4 million liters, implying an increase of more than 25%.
• Year-end target capacity for TIDES solid-phase peptide synthesis reactors130kLContinued expansion from 100kL in the third quarter of 2025.
• Expected full-year TIDES revenue growth45%Previously 40%; the first and second quarters grew 6% and 75% YoY, respectively.
• Full-year capex budgetRmb7.5bn to Rmb8.5bnBoth ends of the range were raised by Rmb1.0bn, mainly for overseas and chemistry business expansion.
• New compounds synthesized for customers over the past 12 monthsOver 440,000Reflects early-stage experimental demand driven by AI-enabled drug discovery.
• Conversion from R stage to D stage in the first half of 2026155 moleculesUsed to monitor R&D project progress.
• Commercial contracts9512 new contracts added in the first half of 2026.
• Small-molecule R&D and manufacturing revenue growth73% YoYThe company expects this trend to continue in 2026.
• Target price and closing priceRmb175.00 / Rmb128.50Closing price as of August 3, 2026, implying potential upside of approximately 36.2%.

Impact & implications

The substantial guidance upgrade and rapid adjusted profit growth indicate improving operating leverage. Continued capacity expansion and higher capex help meet demand from small molecules, TIDES, and overseas customers, while an increase in commercial contracts can extend project lifecycles and improve revenue stability. If capacity utilization continues to rise, there remains room for margin expansion; however, faster capital deployment also raises requirements for order conversion and utilization ramp-up.

Risks

• End-market sales of products tied to important commercial contracts may fall short of expectations or come under pressure due to loss of exclusivity.
• Fluctuations in VC/PE financing may weaken early-stage biotech customers' R&D spending capacity.
• Changes in China-US relations may affect cross-border orders, customer decisions, and overseas expansion.
• After capex accelerates, if order conversion or capacity utilization improvement is slower than expected, investment returns and margins may be affected.
• Morgan Stanley has shareholding, underwriting, and service relationships with WuXi AppTec Co Ltd, and investors should be aware of potential conflicts of interest.

What to watch

• Whether full-year revenue growth from continuing operations can reach the latest guidance of 35% to 39%.
• Whether small-molecule reactor capacity can reach 5 million liters by year-end, and the utilization ramp-up of new capacity.
• Whether TIDES reactor capacity can reach 130kL and full-year revenue growth can reach 45%.
• Whether the number of commercial contracts and small-molecule R&D and manufacturing revenue can sustain high growth.
• The number of projects converting from R stage to D stage and changes in AI-related customer demand.
• Execution progress of Rmb7.5bn to Rmb8.5bn in capex, overseas expansion, and construction of the Changzhou base.
• The China-US policy environment, VC/PE financing conditions, and end-market sales performance of major commercialized projects.